Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death.
Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C.Clin Cancer Res. 
  2024
10.1158/1078-0432.CCR-24-2582.